Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06042153 · ClinicalTrials.gov registry record · Phase 4
DIALYSIS-TIR Study
A Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 5
- Study locations
NCT06042153 is a Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 43 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT06042153, a Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (5)
Texas
- Davita UT Southwestern - Oak Cliff - Dallas
- DaVita UT Southwestern - East Dallas - Dallas
- DaVita UT Southwestern - Preston - Dallas
- DaVita UT Southwestern - Irving - Irving
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06042153
The ClinicalTrials.gov registry entry for NCT06042153 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06042153 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Texas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06042153 about?
NCT06042153 is a clinical study titled "DIALYSIS-TIR Study". This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Particip...
What is the current status of trial NCT06042153?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2023-12-05. Estimated completion is 2028-09.
What conditions does trial NCT06042153 study?
This clinical trial studies the following conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis.
What interventions are being tested in trial NCT06042153?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06042153?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06042153 being conducted?
This trial has 5 study locations across North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Type 2 Diabetes
All registered trials for this condition
End Stage Renal Disease on Dialysis
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.